Skip to main content

US ClosedU.S. Closed

Healthcare · Biotechnology

Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

52W Range

48thpctl

Volume

0.51×avg

Market Cap

508.86MUSD

P/E Ratio

-2.8TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Kyverna Therapeutics, Inc.

KYTXNASDAQ·USD·Closed

Kyverna Therapeutics, Inc.

KYTXNASDAQ·USD·Closed

$8.37

−3.13%

$8.37

−$0.27 (3.13%)

52W Range

48thpctl

Volume

0.51×avg

Mkt Cap

508.86MUSD

P/E

-2.8TTM

Div Yield

–ann

KYTX: Kyverna Therapeutics, Inc. Stock Analysis | finqOS